Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson
Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, Sept. 13, 2018 -- In the ongoing challenge to combat the almost...
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018
HOUSTON, Aug. 13, 2018 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial
HOUSTON, Aug. 09, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066
HOUSTON, July 31, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia
HOUSTON, July 18, 2018 -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover
HOUSTON, July 11, 2018 -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Selected for the Russell Microcap Index
HOUSTON, June 26, 2018 -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market
HOUSTON, June 21, 2018 -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, all of which are based on license agreements with The University of...
Moleculin Receives Approval for Leukemia Clinical Trial
HOUSTON, June 20, 2018 -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors
HOUSTON, June 12, 2018 -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...